UNSPSC 51201569: Atlizumab or tocilizumab

This classification denotes a monoclonal antibody with the molecular formula C6428H9976N1720O2018S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I031V2H011, more generally known as tocilizumab. European Medicines Agency schedules tocilizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20313. The term TOCILIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.

Atlizumab or tocilizumab bears US NLM identifiers UMLS ID C1609165 and NCI Concept Code C84217.

UNSPSC 51201569 Atlizumab or tocilizumab is a Commodity code for pharmaceutical products, yet the recent state and local opportunities tagged under it show a fundamental mismatch: the code nominally covers specific biologic immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions, but recent solicitations are actually buying athletic training services, first-aid medical supplies, and pharmacy benefit management program intelligence. The code shows little relevant recent activity aligned with its pharmaceutical scope.

The three most recent opportunities—the City of Tucson's RFP for athletic training services for fire and police departments (due June 9, 2026), the City of Tampa's ITB for medical aid supplies including bandages and pain relievers (due April 9, 2025), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026)—represent distinct procurement streams unrelated to the biologic drugs the code is intended to classify. None of these solicitations reference atlizumab, tocilizumab, or comparable immunosuppressive therapies. Business development professionals evaluating this code should treat it as inactive for practical state and local procurement purposes and focus instead on the distinct UNSPSC codes that classify the actual categories being bought: athletic training and rehabilitation services, medical and first-aid supplies, and pharmacy benefit management services.